An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
CONCLUSION: In N3 stage NPC, induction chemotherapy and sequential Nimotuzumab plus concurrent chemoradiotherapy yielded an excellent survival benefit, and the toxicities were tolerable. Distant metastasis was the main cause of treatment failure.
PMID: 30610791 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Anemia | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Hematology | Intensity-Modulated Radiation Therapy | Nasopharyngeal Cancer | Radiation Therapy | Skin | Study | Taxotere | Thrombocytopenia | Toxicology | Vasculitis | Xerostomia